synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
RCO2R' + NH2R″ → RCONHR″ + R'OH This reaction is not usually reversible. Hydrazines and hydroxylamine can be used in place of amines. Esters can be converted to isocyanates through intermediate hydroxamic acids in the Lossen rearrangement. Sources of carbon nucleophiles, e.g., Grignard reagents and organolithium compounds, add readily to the carbonyl.
=== Pharmacokinetics === Opipramol is rapidly and completely absorbed by the gastrointestinal tract. The bioavailability of opipramol amounts to 94%. After single oral administration of 50 mg, the peak plasma concentration of the drug is reached after 3.3 hours and amounts to 15.6 ng/mL. After single oral administration of 100 mg the maximum plasma concentration is reached after 3 hours and amounts to 33.2 ng/mL. Therapeutic concentrations of opipramol range from 140 to 550 nmol/L. The plasma protein binding amounts to approximately 91% and the volume of distribution is approximately 10 L/kg. Opipramol is partially metabolized in the liver to deshydroxyethylopipramol. Metabolism occurs through the CYP2D6 isoenzyme. Its terminal half-life in plasma is 6–11 hours. About 70% is eliminated in urine with 10% unaltered. The remaining portion is eliminated through feces.
Peukert argued that societies that have reached "classical modernity" are characterized by advanced capitalist economic organization and mass production, by the "rationalization" of culture and society, massive bureaucratization of society, the "spirit of science" assuming a dominant role in popular discourses, and the "social disciplining" and "normalization" of the majority of ordinary people. Peukert was greatly influenced by the theories of Max Weber, but unlike many other scholars, who saw Weber attempting to rebut Karl Marx, he viewed Weber's principal intellectual opponent as Friedrich Nietzsche. Peukert wrote that for Weber, the principal problems of modern Germany were: The increasing "rationalization" of everyday life via bureaucratization and secularism had led to a "complete demystification of the world". The popularity of the "spirit of science" had led to a misguided belief that science could solve all problems within the near-future. Contrary to the "Bielefeld School", Peukert argued by the time of the Weimar Republic, Germany had broken decisively with the past, and had become a thoroughly "modern" society in all its aspects. Peukert argued that the very success of German modernization inspired by the "dream of reason" meant the contradictions and problems of "classical modernity" were felt more acutely in Germany than elsewhere. For Peukert, the problems of "classical modernity" were:
Sources: en.wikipedia.org
=== Applications === The triple-stranded DNA regions can be generated through the association of Triplex Forming Oligonucleotides (TFO) and Peptide Nucleic Acids (PNAs). Historically, TFO binding has been shown to inhibit transcription, replication, and protein binding to DNA. TFOs tethered to mutagens have also been shown to promote DNA damage and induce mutagenesis. Although TFO have been known to hinder transcription and replication of DNA, recent studies have shown that TFO can be utilized to mediate site specific gene modifications both in vitro and in vivo. Another recent study has also shown that TFOs can be used for suppression of oncogenes and proto-oncogenes to reduce cancer cell growth. For example, a recent study has used TFOs to reduce cellular death in hepatoma cells through the decreasing the expression of MET. PNA TFOs have the ability to enhance recombination frequencies, leading to targeted, specific editing of genes. The PNA-DNA-PNA triplex helix is able to be recognized by the cell's own DNA repair mechanism, which sensitizes the surrounding DNA for homologous recombination. In order for a site-specific PNA structure to mediate recombination within a DNA sequence, a bis-PNA structure can be coupled with a 40nt DNA fragment that is homologous to an adjacent region on the target gene. The linking of a TFO to a donor DNA strand has been shown to induce recombination of the targeted gene and the adjacent gene target region.
homoserine + NAD(P)+ Homoserine represents another branch in the aspartate pathway, as it can progress down one of two pathways to eventually become one of two amino acids: threonine or methionine. This aspartate pathway is present in plants and bacteria, allowing them to synthesize lysine, methionine, and threonine. This pathway is not present in humans or other animals, however. The lack of this pathway means that humans need to take in these amino acids through their diet, which is why they are called essential amino acids.
It induces excitotoxicity in rodents by overactivating NMDA and metabotropic glutamate receptors, leading to calcium overload and oxidative damage. In contrast, it targets glutamate-gated chloride channels in invertebrates, causing increased chloride permeability without affecting their excitatory glutamate receptors.
Sources: en.wikipedia.org
=== Cancer === As of 2023, regulatory agencies, including the FDA and EFSA, and the US National Cancer Institute, have concluded that consuming aspartame is safe in amounts within acceptable daily intake levels and does not cause cancer. These conclusions are based on various sources of evidence, such as reviews and epidemiological studies finding no association between aspartame and cancer. In July 2023, scientists for the International Agency for Research on Cancer (IARC) concluded that there was "limited evidence" for aspartame causing cancer in humans, classifying the sweetener as Group 2B (possibly carcinogenic). The lead investigator of the IARC report stated that the classification "shouldn't really be taken as a direct statement that indicates that there is a known cancer hazard from consuming aspartame. This is really more of a call to the research community to try to better clarify and understand the carcinogenic hazard that may or may not be posed by aspartame consumption." The Joint FAO/WHO Expert Committee on Food Additives (JECFA) added that the limited cancer assessment indicated no reason to change the recommended acceptable daily intake level of 40 mg per kg of body weight per day, reaffirming the safety of consuming aspartame within this limit.
Thomas, a solicitor from Tenterfield, New South Wales, had been retained to defend Maj. Lenahan. The night before, however, he agreed to represent all six defendants. The "Visser Incident" was the first case to go to trial. Lt. Morant's former orderly and interpreter, BVC Trooper Theunis J. Botha, testified that Visser, who had been promised his life would be spared, was cooperative during two days of interrogation and his information was found to have been true. Despite this, Morant ordered him shot. In response, Morant testified that he only followed orders to take no prisoners as relayed to the late Captain Hunt by Col. Hubert Hamilton. He alleged that Visser was captured wearing a British Army jacket and that Hunt's body had been mutilated. In response, the court moved to Pretoria, where Col. Hamilton testified that he had "never spoken to Captain Hunt with reference to his duties in the Northern Transvaal". Though stunned, Maj. Thomas argued that his clients were not guilty because they believed that they "acted under orders". In response, Bolton argued that they were "illegal orders" and said, "The right of killing an armed man exists only so long as he resists; as soon as he submits he is entitled to be treated as a prisoner of war." The Court ruled in Bolton's favor. Morant was found guilty of murder. Handcock, Witton, and Picton were convicted of the lesser charge of manslaughter. On 27 February Morant and Handcock were executed by firing squad after being convicted of murdering eight Afrikaner POWs.
Endotracheal intubation may be required if the airway is unstable or hypoxia persists when breathing 100% oxygen. Needle decompression or tube thoracostomy may be necessary to drain a pneumothorax or haemothorax Foley catheterization may be necessary for spinal cord AGE if the person is unable to urinate. Intravenous hydration may be required to maintain adequate blood pressure. Therapeutic recompression is indicated for severe AGE. The diving medical practitioner will need to know the vital signs and relevant symptoms, along with the recent pressure exposure and breathing gas history of the patient. Air transport should be below 1,000 feet (300 m) if possible, or in a pressurized aircraft which should be pressurised to as low an altitude as reasonably possible. Sinus squeeze and middle ear squeeze are generally treated with decongestants to reduce the pressure differential, with anti-inflammatory medications to treat the pain. For severe pain, narcotic analgesics may be appropriate. Suit, helmet and mask squeeze are treated as trauma according to symptoms and severity.
The medication is used to treat clear cell renal cell carcinoma, the most common histological subtype. The treatment phase is continuing treatment beyond three months. The patient has been issued an authority prescription for pazopanib. The patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST). This treatment must be the sole tyrosine kinase inhibitor subsidised for this condition. Pazopanib has also demonstrated initial therapeutic properties in patients with aggressive fibromatosis (desmoid tumor), ovarian and non-small cell lung cancer. However, plans to apply to the EMA for a variation to include advanced ovarian cancer have been withdrawn and a license will not be sought in any country.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.